Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Immunoprecise Antibodies Ltd
(NQ:
IPA
)
1.020
+0.120 (+13.33%)
Streaming Delayed Price
Updated: 3:59 PM EDT, Aug 16, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Immunoprecise Antibodies Ltd
< Previous
1
2
3
4
Next >
ImmunoPrecise Antibodies (IPA) Reports Financial Results and Business Updates for Fourth Quarter and Full Fiscal Year 2024
July 29, 2024
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
ImmunoPrecise Antibodies to Reschedule Financial Results and Recent Business Highlights Report for Fourth Quarter and Fiscal Year-End 2024
July 23, 2024
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
ImmunoPrecise Announces Financing Agreement with Yorkville Advisors Global, LP of up to $3.0 Million Aggregate Principal Amount of Convertible Debentures
July 16, 2024
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
IPA to Report Financial Results and Recent Business Highlights for Fourth Quarter and Fiscal Year End 2024 on July 25th, 2024
July 15, 2024
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
ImmunoPrecise Appoints Kristin Taylor as Chief Financial Officer
June 27, 2024
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
IPA’s Subsidiary BioStrand and PGxAI Announce Strategic Collaboration to Develop First-In-Class AI Model for Pharmacogenomics Recommendations Using LENSai™
June 25, 2024
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
ImmunoPrecise Antibodies Ltd. Subsidiary BioStrand Receives Prestigious 2024 Impact Award for Groundbreaking LENSai™ Technology
June 12, 2024
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
BioStrand, ImmunoPrecise Antibodies’ Subsidiary, Announces Immediate Commercial Offering of Groundbreaking Software with Customizable Interface for AI-Driven Drug Discovery
June 10, 2024
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
IPA’s Subsidiary, BioStrand, Announces Advanced Large Language Model (LLM) for Electronic Health Records (EHR)
June 04, 2024
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
Epitope Binning Powered By LENSai TM Technology Can Analyze Over 5,000 Sequences With No Physical Materials Needed, Matches Classical Wet Lab Binning Results
April 22, 2024
Via
ACCESSWIRE
ImmunoPrecise Antibodies And InterSystems Partner To Leverage AI In Life Sciences, Transforming Patient Care With Accelerated Discovery And Delivery Of Treatments
April 12, 2024
Via
ACCESSWIRE
InterSystems and IPA’s Subsidiary BioStrand Collaborate to Unveil the Innovative Integration of Vector Search with LENSai for AI-Driven Healthcare Applications
March 28, 2024
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
IPA Acquires the Carterra LSA® Instrument to Enhance Antibody Discovery and Bolster Its AI Developments
March 20, 2024
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
IPA Reports Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2024*
March 14, 2024
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
ImmunoPrecise Antibodies (NASDAQ:IPA) Subsidiary BioStrand Introduces Breakthrough AI Model In Life Sciences, Harnessing LLM Stacking And HYFT Technology
March 08, 2024
Via
ACCESSWIRE
IPA’s subsidiary BioStrand Unveils Major Breakthrough in Life Sciences with Advanced Foundation AI Model Utilizing LLM Stacking and HYFT Technology
March 07, 2024
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
IPA to Report Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2024 on March 14, 2024
March 04, 2024
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
ImmunoPrecise Antibodies (NASDAQ:IPA) Is Changing How We Look At The Complex World Of Antibody Discovery
February 13, 2024
Via
ACCESSWIRE
ImmunoPrecise Antibodies Reports A 19.9% Revenue Increase As It Launches The Next Phase Of LENSai Portal And SaaS Platforms
January 10, 2024
Via
ACCESSWIRE
IPA Reports Financial Results and Recent Business Highlights for Second Quarter Fiscal Year 2024*
December 14, 2023
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
IPA Announces Closing of $1.265 Million Public Offering of Common Shares
December 08, 2023
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
ImmunoPrecise Antibodies Welcomes Mitch Levine To Its Board Of Directors, To Announce Quarterly Results On December 14
December 07, 2023
Via
ACCESSWIRE
IPA Announces Pricing of $1.1 Million Public Offering of Common Shares
December 06, 2023
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
IPA Announces Proposed Public Offering of Common Shares
December 05, 2023
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
ImmunoPrecise Antibodies Ltd. Announces Key Board and Board Committee Chair Appointments and Second Quarter 2024 Earnings Release Call
November 27, 2023
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
ImmunoPrecise’s BioStrand(R) Unifies Diverse Data Modalities, Launches AI-Driven Platform For Enhanced Drug Discovery
November 22, 2023
Via
ACCESSWIRE
BioStrand® Unveils a Revolutionary Approach to Biological Sequence Retrieval: A Fusion of Natural Language Processing and Database Research
November 13, 2023
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
IPA’s Subsidiary, BioStrand, Provides an Update on LENSai™
October 25, 2023
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
IPA Provides Update on Growth Strategy and Recent Share Price Movement
October 23, 2023
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
Overcoming the Information Integration Dilemma: Revolutionizing The Fusion Of Complex Biological Data
October 20, 2023
Via
ACCESSWIRE
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.